What is DA Davidson’s Estimate for USNA Q1 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at DA Davidson issued their Q1 2025 earnings estimates for USANA Health Sciences in a research report issued to clients and investors on Tuesday, February 25th. DA Davidson analyst C. Xue anticipates that the company will post earnings per share of $0.83 for the quarter. DA Davidson currently has a “Neutral” rating and a $38.00 target price on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share.

Several other research firms have also issued reports on USNA. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

USANA Health Sciences Price Performance

Shares of USNA opened at $31.90 on Wednesday. The business has a 50-day moving average of $33.65 and a 200-day moving average of $36.64. USANA Health Sciences has a 1 year low of $30.13 and a 1 year high of $50.32. The company has a market capitalization of $607.96 million, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million.

Hedge Funds Weigh In On USANA Health Sciences

Institutional investors have recently made changes to their positions in the stock. Creative Planning bought a new stake in USANA Health Sciences in the 3rd quarter valued at about $394,000. Allspring Global Investments Holdings LLC grew its stake in USANA Health Sciences by 14,068.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company’s stock valued at $1,472,000 after acquiring an additional 38,547 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of USANA Health Sciences by 13.5% during the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock valued at $4,702,000 after acquiring an additional 14,756 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of USANA Health Sciences by 44.1% during the third quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company’s stock worth $336,000 after purchasing an additional 2,713 shares during the period. Finally, KBC Group NV lifted its holdings in shares of USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after purchasing an additional 519 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.